The Relative Strength (RS) Rating for Illumina climbed into a higher percentile Monday, as it got a lift from 65 to 71.
This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks compares to the rest of the market.
Decades of market research reveals that the best stocks often have an RS Rating of at least 80 as they begin their biggest price moves. See if Illumina can continue to rebound and clear that threshold.
Can You Really Time The Stock Market?
Illumina is trying to complete a consolidation with a 156.66 buy point. See if it can break out in volume at least 40% higher than normal.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 13% to 245%. Revenue rose from -5% to -3%.
Illumina earns the No. 7 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Medpace Holdings are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
